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ABSTRACT
Distant metastases arise in 20-30% of patients with squamous cell carcinoma of 
the head and neck (HNSCC) in the 2 years following treatment. Therapeutic options 
are limited and the outcome of the patients is poor. The identification of predictive 
biomarkers of patient at risk for distant metastasis and therapies are urgently needed. 
We previously identified a clinical subgroup, called “R1” characterized by high 
propensity for rapid distant metastasis. Here, we showed that “R1” patients do not 
or at very low level express caveolin-1 (Cav1). Low or no expression of Cav1 is of bad 
prognosis. Disappearance of Cav1 enables cells to undergo epithelial-mesenchymal 
transition (EMT). EMT is associated with enhanced migration and invasion. Our study 
uncovered a new target, α5β1 integrin. Targeting α5β1 integrins might not only prevent 
metastasis of HNSCC but also delay the development of the primary tumor by reducing 
tumor cell viability. Cav1 detection might be taken into consideration in the future 
in the clinic not only to identify patients at high risk of metastasis but also to select 
patient who might benefit from an anti-integrin therapy.
INTRODUCTION
Head and neck squamous cell carcinomas (HNSCC) 
arise from the epithelium of the upper digestive tract, 
including the oral cavity, the pharynx and the larynx. With 
over 600,000 new cases diagnosed each year, HNSCC is 
the 6th most frequent malignancy in the world. Tobacco 
and alcohol are two important risk factors responsible 
for 72% of HNSCC cases [1]. Human papilloma virus 
(HPV) was recently shown as a causative agent for 26% 
of HNSCC [2]. In the absence of suitable biomarkers, 
therapeutic decisions are based on tumor localization and 
TNM staging (evaluation of tumor size (T), lymph node 
involvement (N) and the presence of distant metastases 
(M)). However, lesions with similar pathological features 
can differ in clinical outcome. Despite advances in the 
understanding of the molecular features of HNSCC 
along with improved treatments, the survival rate has 
been unchanged in the past 30 years. Lymph node 
metastasis (LNM) detected in 50% of patients at the 
time of diagnosis and distant metastases observed in 
about 20-30% of patients 2 years after the treatment 
of the primary tumor account for such persistent bad 
prognosis. The 5-year survival rate is 54% for patient 
with LNM and 32% for patients with distant metastasis 
[3]. Chemoradiation regimens have become a standard of 
care for the management of locally advanced HNSCC (for 
review [4] and references therein). However, the prognosis 
of recurrent/metastatic HNSCC remains poor, and few 
therapeutic options are available. Induction chemotherapy 
followed by chemoradiotherapy has been shown to have a 
Oncotarget41885www.impactjournals.com/oncotarget
benefit in the reduction of distant metastasis [5]. However, 
the therapeutic index (efficacy vs. toxicity ratio) of these 
protocols is poor. Thus, the identification of molecular 
prognostic biomarkers and potential alternative drug 
targets should help to guide therapeutic choices and 
identify patients who will most benefit from innovative 
therapeutic approaches and avoid aggressive treatments. 
To identify prognostic HNSCC molecular subgroups 
and potential biomarkers, we have recently conducted 
genome-wide integrated analysis of four omic data sets 
[6]. The integrated analysis of 3 omics (methylome, 
transcriptome and miRNome) uncovered a common robust 
subgroup of patients, called “R1”, which is characterized 
by high propensity for rapid distant metastasis. The way 
tumor cells interact with and modify their environment is 
a key issue in the acquisition of metastatic properties. In 
accordance, “R1” tumors are characterized by alterations 
of pathways involved in cell-cell adhesion, extracellular 
matrix (ECM), epithelial-to-mesenchymal transition 
(EMT), immune response and apoptosis [6]. Similarly, 
alterations of genes controlling adhesion, motility and 
invasiveness especially integrins were reported as the 
major molecular differences among metastatic and non-
metastatic HNSCC tumors [7-9].
We previously reported that stronger adhesion, 
motility and invasiveness can be observed in glioblastoma 
expressing high levels of α5β1 integrins induced 
by the disappearance of Cav1 from cells [10, 11]. 
Subclassification of patients according to α5β1 integrins/
Cav1 levels showed the existence of a cluster of patients 
exerting low Cav1/high α5β1 integrins levels [11] which 
was correlated with reduced overall survival [12]. Cav1 
is the principal structural protein of caveolae able to 
control the subcellular distribution, activity and expression 
of molecules and receptors [13, 14]. Cav1 regulates 
therefore multiple cancer-associated processes including 
cellular transformation, tumor growth, cell migration and 
metastasis, cell death and survival, multidrug resistance 
and angiogenesis [15, 16]. Up-regulation of Cav1 is 
associated with metastatic disease progression of various 
cancers and appears therefore as a good promoter of 
tumor dissemination [17, 18, 19, 20]. In contrast, reduced 
expression of Cav1 was observed in HNSCC LNM 
[21, 22], correlates with breast cancer nodal metastasis 
[23] and is prometastatic in malignant melanoma [24]. 
Downregulation of Cav1 induced EMT and enhanced 
tumor cell invasion in various cancer cell lines [25]. 
We therefore addressed the role of Cav1 in the 
regulation of HNSCC metastasis in the metastatic-prone 
“R1” and the non metastatic prone “non-R1” subgroups 
and investigated the molecular mechanisms underlying the 
acquisition of the metastatic phenotype. 
RESULTS
Cav1 expression is reduced in prometastatic tissue
Analysis of Cav1 expression using a real-time qRT-
PCR approach on RNA extracts from fresh-frozen tumours 
confirmed a strong and significant decrease of Cav1 
expression in “R1” patients as compared to “non-R1” 
tumours (Figure 1A). Downregulation of Cav1 was further 
confirmed by immunohistochemical (IHC) analysis in 
the corresponding formalin fixed paraffin embedded 
(FFPE) tissues (Figure 1B). “Non-R1” tumors expressed 
Cav1 both at the plasma membrane and in the cytosol, 
with variable staining intensity. Cav1 staining was found 
to be largely weaker in “R1” tumour specimen. A semi-
quantitative analysis of IHC staining was performed and 
tumours were classified in 4 categories according to the 
percentage of Cav1-positive carcinoma cells: 0%; 1-25%; 
26-75%; > 75%. A majority of “non-R1” specimens 
showed > 75% of Cav1-positive cells, whereas no “R1” 
tumours belonged to that later category. This differences 
were found to be statistically significant (Figure 1B, χ2 
test p = 0,007). Patients were stratified according to the 
Cav1 gene expression (see suppl. material and methods for 
cut-off value determination), and a Kaplan-Meier analysis 
of the distant metastasis-free survival (MFS) and of the 
overall survival (OS) were performed. Cav1 was found 
to have a prognosis value, since low caveolin expression 
correlated to adverse prognosis (shorter time to metastasis; 
p < 0.001; Figure 1C) and reduced OS (p < 0.005; Figure 
1D).
Low Cav1 expression increases cell motility and 
invasion
In order to evaluate the impact of the deregulation of 
Cav1 expression on the propensity of tumour cells to form 
distant metastasis, we generated a cell line expressing low 
level Cav1 and performed functional analysis (shRNAcav1-
SCC9, Figure 2A). Migration was analyzed in single and 
collective cell migration assays. Individual cell migration 
was examined by live cell imaging in low density cell 
cultures (Figure 2B). Cell tracking measurements revealed 
that shRNAcav1-cells have a more persistent migration 
and a significant increase in the speed and velocity of 
migration than their control counterparts (Figure 2B). In 
other terms SCC9-shRNAcav1 explored larger areas than 
control cells. Consequences of Cav1 reduction were 
also determined in a collective 3D cell migration model 
using SCC9 spheroid. SCC9-shRNActrl poorly migrated 
out of the spheres on plastic or fibronectin (FN)-coated 
dishes but strongly on collagen-coated dishes (Figure 
2C). Independently of the matrix used, shRNAcav1-cells 
migrated out of aggregates more efficiently and covered 
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Figure 1: Cav1 expression in human HNSCC tissue specimens. A. Quantified analysis of CAV1 transcripts determined in 11 
primary tumor samples of patients that developed metastasis (“R1”) and 57 primary tumor samples of patients that did not developed 
metastasis (“non-R1”). The line within the bar represents the mean value and “ᴏ” represent individual data point. (***p < 0.001). B. 
Immunohistochemical analysis of Cav1 in R1 and non-R1 FFPE tissus (original magnification: X100). Table show % of non-R1 and R1 
tumors with 0%, 1-25%, 25-75% and >75% Cav1-positive cells. C. Kaplan-Meier analysis of the distant metastasis-free survival (MFS) 
in patients stratified according Cav1 gene expression (CAV1(+) and CAV1 (-)). A cut-off value was determined for Cav1 gene expression 
(measured by qRT-PCR), corresponding to a 90.1% sensitivity and a 81.4% specificity with respect to the “R1” status (i.e. 90.1% of the 
“R1” lesions display a Cav1 expression level below this cut-off, and 81.4% of the “non-R1” tumours express Cav1 levels above this cut-
off. More detail in suppl. material and methods). Samples were considered as Cav1-negative is the qRT-PCR value was ≤ to the cut-off. 
Shorter time to metastasis ***p < 0.001). D. Kaplan-Meier analysis of the overall survival (OS) in patients stratified according Cav1 gene 
expression (CAV1(+) and CAV1 (-)) as described in Fig 1C. Shorter time to death, **p = 0.003) 
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Figure 2: Reduction of Cav1 enables cells motile and invasive properties. A. Quantitative determination of transcripts and 
protein expression of Cav1 in shRNActrl- or shRNAcav1-SCC9 cells using qRT-PCR with RNA18S as control and western blot using 
GAPDH as a loading control. Each bar represents the mean±SEM with ***p < 0.001. B. Analysis of single cell migration of shRNActrl- and 
shRNAcav1-transfected SCC9. Diagrams represent the migrating trajectories of cells covered during 6 hours by ten representative shRNActrl 
and shRNAcav1-transfected SCC9. Each bar represents the mean±SEM of the speed, the velocity and the persistence recorded during 6 hours 
for each cell type (n = 4, *p < 0.05). C. Analysis of collective cell migration of shRNActrl- and shRNAcav1-transfected SCC9. Phase contrast 
images showing the evasion of shRNActrl- and shRNAcav1-transfected SCC9 from spheroids after 12 hours growth on plastic-, fibronectin- 
or collagen-coated cells. Each bar represents the mean±SEM area covered by cells evading from the spheroid (n = 7-9, *p < 0.05, **p 
< 0.01 and ***p < 0.001). D. Left panel: quantitative determination of transcripts and protein expression of fibronectin in shRNActrl- or 
shRNAcav1-SCC9 cells using qRT-PCR with RNA18S as control and western blot using tubulin as a loading control. Each bar represents 
the mean±SEM with ***p < 0.001, n = 8. Right panel: immunofluorescence analysis of extracellular secreted fibronectin by shRNActrl- or 
shRNAcav1-SCC9 cells. Images were taken at 4x magnification with an AXIO Zeiss microscope. E. Phase contrast images showing the 
invasion of shRNActrl- and shRNAcav1-transfected SCC9 through BioCoat Matrigel® invasion chambers. Cells were stained with crystal 
violet after 22 hours invasion. Each bar represents the mean±SEM fold increase in invasion (n = 6, **p < 0.01). F. MMPs protein levels 
were analyzed by western blot analysis using GAPDH as a loading control. Each bar represents the mean±SEM with *p < 0.05 and ***p < 
0.001. MT1-MMP was analyzed in shRNActrl- or shRNAcav1-SCC9 cells using qRT-PCR with RNA18S as control. Each bar represents the 
mean±SEM with *p < 0.05, n = 4. 
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an area significantly more important than control cells 
(Figure 2C). Data suggested that although collagen 
promoted strong evasion of cells, removal of Cav1 not 
only reinforced the process on collagen but also conferred 
cells the capacity to efficiently and significantly evade 
on a new matrix, FN. A strong secretion of FN into the 
extracellular environment was observed by microscopy in 
shRNAcav1-cells although no increased expression of FN 
was detected at the RNA and protein levels (Figure 2D). 
To ascertain the role of Cav1 in the migration of 
HNSCC through 3D matrixes, matrigel® invasion assays 
were performed. shRNAcav1-cells navigated through 
matrigel® more efficiently than their control counterpart 
(Figure 2E). As invasion requires the degradation of 
underlying basement membrane, expression of matrix 
metalloproteases (MMPs) was analyzed. The reduction 
of Cav1 expression was associated with the apparition 
of an active cleaved MMP2 and a significant decrease of 
pro-MT1-MMP and pro-MMP9 (suggesting the activation 
of those MMP) in shRNAcav1-cells compared to control 
cells (Figure 2F). MT1-MMP transcript was significantly 
increased in shRNAcav1-cells (Figure 2F right panel). 
Altogether data showed that extinction of Cav1 in HNSCC 
resulted in enhanced migratory capacity and invasiveness.
Low Cav1 expression induces the expression of 
specific integrins required for efficient migration 
and invasion
Acquisition of invasiveness is crucial for metastatic 
dissemination. Invasion requires the modulation of cell-
ECM adhesions mainly dependent on integrins. We 
previously reported that depletion of Cav1 significantly 
modified the expression of integrins in glioblastoma [10, 
11]. shRNAcav1-cells expressed significantly more α2, α5, β1 
and β3 integrin subunits than control cells at the RNA and 
protein level (Figure 3A). α3, α5, α7 and β5 integrin subunits 
were not significantly altered (Figure 3A). αv integrin 
subunit was increased at the RNA level but decreased 
discreetly at the protein level in shRNAcav1 versus 
shRNActrl (Figure 3A). Data suggested that two integrins 
were strongly increased following extinction of Cav1, α2β1 
and α5β1 integrins. Those integrins were probably involved 
in the increase of cell migration on collagen and FN.
We ought to determine if resulting increased motile 
and invasive capabilities are dependent on those integrins. 
Cell tracking measurements revealed that compound 1, an 
antagonist of α5β1 integrin, totally abolished the increased 
speed of migration observed in shRNAcav1-cells without 
affecting basal migration of control cells (Figure 3B). 
Compound 1 did not affect velocity or persistence of cells 
as previously reported (Figure 3B, [26]). Data suggested 
that α5β1 integrin might be the integrin responsible for 
acquired motility of shRNAcav1-cells.
Consequences of α5β1 integrin inhibition (using an 
antibody blocking selectively the β1 integrin subunits and 
compound 1) were also determined in the collective cell 
migration model. Although migration of SCC9-shRNActrl 
was not significantly altered by any drugs on FN-coated 
plates, evasion of SCC9-shRNAcav1 cells was abolished 
by the β1 antibody and by compound 1 (Figure 3C, 
left). Evasion of both cell lines was abolished by the β1 
antibody but not compound 1 on collagen-coated plates 
(Figure 3C, middle). The involvement of α2β1 integrin in 
the increased motility of cells on collagen was determined 
after silencing α2β1 integrin (siRNAα2 versus siRNActrl, 
suppl. data 1). In contrast with K34c that only affected the 
evasion of SCC9-shRNAcav1 on FN, silencing α2β1 integrin 
reduced the evasion of both SCC9-shRNActrl (by 31.5%) 
and SCC9-shRNAcav1 (by 52.9%, Figure 3C, right). The 
increase of cell migration observed in SCC9-shRNAcav1 
cells on both collagen and FN are linked to the increase of 
α2β1 and α5β1 integrin expression. 
Blocking α5β1 integrin with another non peptidic 
α5β1 integrin antagonist, K34c, also totally abolished the 
invasive capacity of shRNAcav1-cells in 3D matrigel
® 
invasion assays (Figure 3D). K34c remained without 
effect on basal invasion of control cells. Silencing α5 
integrin subunits or inhibiting α5β1 integrin using K34c did 
not affect either basal levels of MT1-MMP or MT1-MMP-
induced expression in shRNAcav1-cells suggesting that the 
induction of MMPs was driven by Cav1 independently 
of integrins activation (Figure 3E). Data suggested that 
the extinction of Cav1 in HNSCC resulted in enhanced 
migratory capacity and invasiveness that is dependent of 
α5β1 integrin.
To ascertain that the alteration of α5β1 integrin 
expression observed following depletion of Cav1 had 
clinical significance, we performed IHC analysis in the 
corresponding FFPE tissues. “Non-R1” tumors which 
expressed Cav1 showed no or weak α5 integrin subunit 
expression. “R1” tumours specimen which express weak 
or no Cav1 exert α5 integrin subunit staining confirming in 
vitro data (Figure 3F).
Low Cav1 expression forces HNSCC cells to 
undergo an EMT
Enhanced migration and invasion, increased 
production of ECM and degradation of underlying 
basement membrane are multiple biochemical changes of 
a biological process allowing a polarized epithelial cell to 
acquire a mesenchymal phenotype so called EMT. Cav1 
reduction in SCC9 resulted in a switch from a cuboid 
epithelial shape to a more fibroblastic appearance (Figure 
4A). EMT was associated with a loss of E-cadherin 
and a reduction of β-catenin expression (Figure 4B). 
Simultaneously, the mesenchymal marker vimentin 
was significantly increased (Figure 4B). Analysis of 
the expression of key transcriptional regulators of EMT 
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Figure 3: Integrins are involved in the motile and invasive properties of low Cav1 expressing cells. A. Left panel: 
quantitative determination of transcripts expression of integrins (α2, α5, α6, α7, αv, β1, β3, β5 integrin subunits) in shRNActrl- or shRNAcav1-
SCC9 cells using qRT-PCR with RNA18S as control. Each bar represents the mean±SEM with *p < 0.05, and ***p < 0.001. Right panel: 
integrin subunit protein levels (α2, α3, α5, αv, β1 and β3 integrin subunits) were analyzed by western blot analysis using GAPDH as a loading 
control. Each bar represents the mean±SEM with **p < 0.01 and ***p < 0.001. B. Analysis of single cell migration of shRNActrl- and 
shRNAcav1-transfected SCC9. Migrating trajectories of shRNActrl- and shRNAcav1-transfected SCC9 exposed to solvent or to a specific 
α5β1 integrin antagonist component 1 (C1, 20µmol/L) were recorded during 6 hours. Each bar represents the mean±SEM of the speed, 
the velocity and the persistence recorded during 6h for each cell type (n = 3-5, *p < 0.05 and **p < 0.01). C. Analysis of collective cell 
migration of shRNActrl and shRNAcav1-transfected SCC9. Evasion of shRNActrl- and shRNAcav1-transfected SCC9 from spheroids exposed 
to solvent, to a specific α5β1 integrin antagonist component 1 (C1, 20 µmol/L) and to a β1 integrin specific blocking antibody OS2966 
(10 µg/mL) were determined after 12 hours growth on fibronectin- or collagen-coated cells. Evasion of shRNActrl- and shRNAcav1-SCC9 
transfected with siRNActrl or siRNAα2 from spheroids were determined after 12 hours growth on collagen-coated cells. Each bar represents 
the mean±SEM area covered by cells evading from the spheroid (n = 4, *p < 0.05, **p < 0.01 and ***p < 0.001). D. Phase contrast images 
showing the invasion of shRNActrl- and shRNAcav1-transfected SCC9 exposed to solvent or to a specific α5β1 integrin antagonist K34c (20 
µmol/L) through BioCoat Matrigel® invasion chambers. Cells were stained with crystal violet after 22 hours invasion. Each bar represents 
the mean±SEM fold increase in invasion (n = 4-6, *p < 0.05 and **p < 0.01). E. Quantitative determination of transcripts expression of 
MT1-MMP in shRNActrl- or shRNAcav1-SCC9 cells transfected with siRNActrl and siRNAα5 integrin subunits or exposed to solvent and 
K34c (20 µmol/L) using qRT-PCR with RNA18S as control. Each bar represents the mean±SEM with *p < 0.05 and ***p < 0.001. F. 
Immunohistochemical (IHC) analysis of Cav1 (left panels) and α5 integrin subunit (middle panels) in representative “R1” and “non-R1” 
FFPE tissues are shown (original magnification: X200). Magnifications of insets shown in middle pictures are shown in the corresponding 
right panels (original magnification: X400).
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showed that shRNAcav1 cells expressed increased level of 
repressors of E-cadherin expression such as Slug, Snail, 
Twist, Zeb1 and Zeb2 (Figure 4C). We concluded that the 
extinction of Cav1 induces HNSCC cells to undergo EMT. 
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We previously showed that the “R1” cluster of patient was 
characterized by alterations of pathways involved in EMT 
[6]. In accordance, a significant reduction of E-cadherin 
expression and an increase of the vimentin/E-cadherin 
ratio were found in “R1” patients compared to “non-R”1 
tumours. In addition, “R1” patients exhibited significantly 
higher levels of Twist than “non-R1” tumours. Twist 
expression was found to be anti-correlated with Cav1 
expression. Altogether, patient data confirmed in vitro 
studies showing an induction of EMT in “R1” tumors 
depleted in Cav1 (Figure 4D). To go further, we silenced 
both Slug and Twist to determine whether EMT induced 
by suppression of Cav1 is dependent on both transcription 
factors. Inhibition of Slug significantly increased SNAIL 
and TWIST expression in both shRNActrl and shRNAcav1-
SCC9 (Figure 4E). We hypothesise that such an increase 
in EMT markers after Slug inhibition might be due to 
the repression of Cav1 expression by Slug itself (suppl. 
data 2). Slug inhibition did not repress the increase of 
SNAIL, TWIST or ZEB1 in shRNAcav1-SCC9 and did not 
prevent the disappearance of E-cadherin in shRNAcav1-
SCC9. However, Slug inhibition prevented the induction 
of vimentin in shRNAcav1-SCC9 (Figure 4E). Turning to 
Twist, its inhibition did not affect Cav1 expression or the 
increase of Slug, SNAIL, TWIST or ZEB1 in shRNAcav1-
SCC9 and did not prevent the disappearance of E-cadherin 
in shRNAcav1-SCC9 (Figure 4E). Data suggest therefore 
that Slug contribute to the full transition as the absence of 
Slug prevents the appearance of the mesenchymal marker 
vimentin in shRNAcav1-SCC9. 
α5β1 integrin was inhibited using K34c to determine 
its contribution to EMT in shRNAcav1 cells. K34c did not 
affect basal levels of TWIST, Zeb1 or vimentin but slightly 
inhibited Slug, Snail and E-cadherin. K34c only affected 
Slug induction in shRNAcav1-SCC9 cells (Figure 4F). 
Except for Slug, EMT gene expressions were activated 
independently of α5β1 integrin upon Cav1 removal.
Low Cav1 expression is associated with a 
reduction of growth and survival capacities 
partially preserved by α5β1 integrins
Although reduction of Cav1 expression enabled cell 
invasive properties, one striking phenotype of shRNAcav1-
SCC9 cells was a 57% reduction in the growth index of 
cells (Figure 5A) and a 40% reduction in the number of 
colonies in a clonogenic assay (Figure 5B). Although 
shRNAcav1-cells displayed reduced growth and fewer 
colonies, cells retained their ability to self-renew (right 
panel of photographs, Figure 5B) allowing maintenance 
of a population of tumorigenic cells. As α5β1 integrin 
played a crucial role in the acquisition of proliferative and 
clonogenic ability of Cav1-depleted glioma cells [10, 11], 
its role in the reduction of proliferation and clonogenicity 
observed in HNSCC cells with reduced expression of 
Cav1 was determined.
Involvement of α5β1 integrin in the growth and 
colony formation was analyzed using the selective 
antagonist K34c. K34c by itself did not affect basal 
proliferation but slightly reduced viability of control cells 
(Figure 5C). The inhibition of proliferation observed after 
Cav1 depletion was reduced even further in presence 
of K34c most probably because under such conditions 
viability of cells is significantly reduced (Figure 5C). 
As a consequence, surviving fraction of control cells as 
well as shRNAcav1 cells exposed to K34c was significantly 
reduced in clonogenic assays (Figure 5D). Depletion of 
α2β1 integrins did not affect clonogenic survival by itself 
and did not improve or worsened that of shRNAcav1-cells 
(suppl. data 3) suggesting that α5β1 integrins are the main 
integrins involved in the regulation of growth/survival/
clonogenicity of HNSCC cells. Data suggested therefore 
that the reduction of growth and clonogenicity observed 
in shRNAcav1-cells was not due to α5β1 integrins. However 
as the inhibition of α5β1 integrin activity in those cells 
reduced even further the growth and the survival, α5β1 
integrins seems crucial to maintain residual growth and 
survival of shRNAcav1 cells. To conclude, α5β1 integrins 
mediate both motile/invasive and survival properties of 
cells expressing low levels of Cav1. 
Figure 4: Low Cav1 expressing cells undergo an EMT. A. Phase contrast images of stable SCC9 cells expressing shRNActrl or 
shRNAcav1 in culture. B. Quantitative determination of transcripts expression of epithelial (E-cadherin and β-catenin) and mesenchymal 
(vimentin) markers in shRNActrl- or shRNAcav1-SCC9 cells using qRT-PCR with RNA18S as control and western blot using tubulin as 
a loading control. Each bar represents the mean±SEM with **p < 0.01 and *** < p0.001. C. Quantitative determination of transcripts 
expression of key regulator of E-cadherin and EMT (including Slug, Snail, Twist, ZEB1 and ZEB2) in shRNActrl- or shRNAcav1-SCC9 cells 
using qRT-PCR with RNA18S as control. Each bar represents the mean±SEM with **p < 0.01 and ***p < 0.001. D. Quantified analysis of 
E-cadherin, vimentin, Twist and Cav1 transcripts determined in primary tumor samples of patients that developed metastasis (“R1”) and 
primary tumor samples of patients that did not developed metastasis (“non-R1”). The line within the bar represents the mean value and 
“ᴏ” represent individual data point. (***p < 0.001). E. Quantitative determination of transcripts expression of Slug, Snail, Twist, Zeb1, 
vimentin and E-cadherin in shRNActrl- or shRNAcav1-SCC9 cells transfected by siRNActrl or siRNASLUG or siRNATWIST using qRT-PCR with 
RNA18S as control. Each bar represents the mean±SEM with *p < 0.05, **p < 0.01 and *** < p0.001. F. Quantitative determination of 
transcripts expression of Slug, Snail, Twist, Zeb1, vimentin and E-cadherin in shRNActrl- or shRNAcav1-SCC9 cells exposed to DMSO or 20 
µmol/L K34c using qRT-PCR with RNA18S as control. Each bar represents the mean±SEM with *p < 0.05, **p < 0.01 and *** < p0.001.
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Figure 5: Low Cav1 expression is associated with a reduction of growth and survival capacities partially preserved 
by α5β1 integrins. A. shRNActrl- and shRNAcav1-transfected SCC9 growth index was analyzed by regular cell counting using the TC20 
counter (BioRad). Each bar represents the mean±SEM growth index of shRNAcav1- versus shRNActrl-transfected cells (n = 14, ***p < 0.001). 
B. ShRNActrl- and shRNAcav1- SCC9 were subjected to a clonogenic assay. Photograph represents phase contrast images of shRNActrl- and 
shRNAcav1- SCC9 colonies after staining with crystal violet. Each bar represents the mean±SEM surviving fraction of shRNAcav1- versus 
shRNActrl-transfected cells. Plating efficiency are 0.23±0.02, and 0.17±0.02 for shRNActrl and shRNAcav1-transfected SCC9 respectively (n 
= 17, ***p < 0.001). C. Phase contrast images of stable shRNActrl or shRNAcav1 SCC9 cells exposed to solvent or 20 µmol/L K34c up to 72 
hours in 0% FBS containing medium. Each bar represents the mean±SEM number of cells and the percentage of proliferation and viability 
after trypan blue staining with *p < 0.05, **p < 0.01 and *** < p0.001. D. Phase contrast images of shRNActrl- and shRNAcav1- SCC9 
colonies stained with crystal violet exposed to solvent or 20 µmol/L K34c up to 72 hours in 0% FBS containing medium. After refreshment, 
cells are allowed to grow 7 days in 10% FBS containing medium. Each bar represents the mean±SEM surviving fraction with **p < 0.01 
and *** < p0.001.
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DISCUSSION
Therapeutic options for the management of 
metastatic HNSCC are limited, and the outcome of the 
patients is poor. Predictive biomarkers of metastatic 
tumors as well as therapies tied to genetic alterations 
involved in the metastatic process are urgently needed. 
Our study showed that the absence or low expression 
of Cav1 is observed in primary “R1” tumors with high 
propensity for distant metastasis. To date, only a few 
studies addressed the role of Cav1 in the metastatic 
process of HNSCC. However the reported data are 
inconsistent. Masuelli et al. showed that Cav1 is highly 
increased in well and poorly differentiated HNSCC and its 
overexpression was associated with LNM [18]. Increased 
expression of Cav1 was also observed in HNSCC cell lines 
selected for their aggressive metastatic phenotype [27]. 
Silencing Cav1 via lentiviral RNAi miR133a was shown 
to delay tumor growth in vivo, cell migration and invasion 
[28, 29]. On the contrary, significant decrease in Cav1 
expression was observed in poorly differentiated HNSCC 
tumors and in LNM tissues of patients [21] without 
significant differences between primary tumors of patients 
who did or not have LNM. In an earlier study Zhang et 
al. reported a similar loss of Cav1 in cell lines generated 
from LNM tissues [9]. Here, we confirmed that low level 
of Cav1 correlates with adverse prognosis, reduced distant 
MFS and OS. We can therefore hypothesize that Cav1 
expression is dramatically reduced in metastatic tissue 
as compared to primary tumour, as reported by Zhang et 
al. [22], but that this downregulation is also a hallmark 
of metastasis-prone HNSCC before extension to distant 
sites. To our knowledge, our study is the first showing 
rational and clinical evidence that no or low levels of Cav1 
expression in primary HNSCC tumors might be predictive 
of patient with high metastasis risk as well as being of bad 
prognosis. However, due to a small cohort size and the 
retrospective nature of our study, our observations must 
be interpreted with caution. The prognostic power of Cav1 
expression requires confirmation in a larger prospective 
clinical study in newly diagnosed HNSCC patients. IHC 
is a technique routinely used by pathologists for the 
diagnosis of solid tumors, we think that IHC staining of 
Cav1 might be easily translated in the future to the clinic. 
Patients with high nodal stage (N ≥ 2) tumours are at risk 
for distant metastasis. Monitoring the expression of Cav1 
might be a useful tool for a more reliable evaluation of 
tumour propensity for metastasis, and to identify patients 
who could benefit from a new and more personalized 
medicine. For example, Mercier et al. reported that mTOR 
inhibitors such as rapamycin prevented tumor growth and 
increased survival rates in breast cancer patients with 
decrease stromal Cav1 expression [30]. In addition, our 
study showed that drugs targeting α5β1 integrins might 
also be effective in preventing HNSCC metastasis. Here 
we propose a biomarker that could rationally select 
specific subpopulation of HNSCC patients that might be 
responsive to more targeted therapy.
Consistently with patient data, decreased expression 
of Cav1 in HNSCC cell lines heightened pro-metastatic 
features reflected by increased migration, enhanced 
evasion and stronger invasion. Cav1 up-regulation 
enhanced cell mobility/migration, increased directional 
motility and invasion in vitro in Ewing’s sarcoma tumors, 
hepatocellular tumors, lung carcinoma or even HNSCC 
[16]. In contrast, Cav1 promote proliferation whereas it 
suppressed migration and invasion of melanoma cells 
through the inhibition of the integrin/FAK/Src signaling 
pathway [24]. Silencing Cav1 in glioblastoma endowed 
cells mobility and invasion mediated by α5β1 integrins 
[11]. Downregulation of Cav1 induced EMT and enhanced 
tumor cell migration and invasion in various cancer cell 
lines [25]. Increased cell motility coupled to reduced 
growth observed here in HNSCC cells expressing reduced 
Cav1 expression suggest that Cav1 expression in primary 
HNSCC might contribute to tumor growth, whereas its loss 
is a key factor in metastatic progression. Acquisitions of 
migratory and invasive capacities are main characteristics 
of cells undergoing an EMT [31, 32]. Interestingly, beside 
alterations of pathways involved in cell-cell adhesion, 
ECM, immune response and apoptosis, “R1” tumors 
are characterized by alterations of the EMT pathway 
[6]. Cav1 deficiency induces EMT during peritoneal 
dialysis [33] and in HNSCC [21] as well as EndoMT in 
pulmonary endothelial cells [34]. In accordance, reduced 
expression of Cav1 in our model is linked to a loss of 
the cobblestone epithelial morphology, a switch from 
epithelial (E-cadherin) to mesenchymal (vimentin) marker 
expression and the expression of various transcription 
factors such as Twist, Snail, Slug, ZEB1 and ZEB2 
known to orchestrate EMT. Induction of EMT following 
reduction of Cav1 expression might likely be due to the 
release of the TGFβ and/or the ERK1/2 pathways which 
are major inducers of EMT. Both pathways were shown to 
be activated in glioblastoma [10] and in human peritoneal 
cells following Cav1 silencing [33].
The way tumor cells interact with and modify their 
environment is crucial for the metastatic process. Cells 
undergoing type 3 EMT (carcinoma-metastatic transitions) 
are characterized by an integrin switch and a change in the 
extracellular matrix (for review [35]). Reduction of Cav1 
expression in our model led to a change in the expression 
of integrins with the silencing of αv integrins and the 
induction of α5 and α2 integrins. Although the regulation 
of α5β1 integrin expression deserves further studies, it is 
most probable that its overexpression in shRNAcav-1-cells 
is a consequence of EMT in those cells as inhibition of 
α5β1 integrin using K34c could not restore EMT markers at 
the level of control cells in shRNAcav-1-cells. EMT markers 
such as Zeb2 [36], Twist-AP1 [37] and SNAIL [38] were 
all described as direct inducers of α5 integrin expression. 
In addition α5β1 integrin expression was shown to be 
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negatively regulated by E-cadherin [39]. If α5β1 integrins 
did not drive EMT, they seemed to play a crucial role 
in the motile and invasive phenotype acquired by cells 
expressing low level of Cav1 as their ligand FN clearly 
boosted the evasion of shRNAcav-1-cells out of the tumor 
spheres in contrast to control cells. Moreover α5β1 integrin 
inhibition totally prevented shRNAcav-1-cell migration, 
evasion and invasion. Although αvβ1 and αvβ3 integrins can 
also bind FN, it is unlikely that these integrins support the 
metastatic phenotype as the expression of the αv integrin 
subunit is downregulated. α5β1 integrin was recently 
shown to have important role in tumor progression 
[40], metastasis [39] and/or resistance to therapies [41] 
in various cancers. Its involvement in the metastatic 
extension of HNSCC was suggested by Wang et al. who 
showed that FN clearly enhanced the invasive ability of 
β1 integrin expressing cells [42]. Overexpression of this 
integrin indicated a very poor prognosis in epithelial 
ovarian cancer [39] and glioblastoma [12]. In accordance, 
blocking α5β1 integrin activity using specific antagonist 
such as K34c and compound 1, used to successfully block 
this integrin in other model of solid tumors [10-12, 26, 
43], strongly impaired single cell migration, evasion and 
invasion suggesting that α5β1 integrin is the main integrin 
involved in the motility and invasiveness of shRNAcav-
1-cells. As shown in glioblastoma, depletion of Cav1 in 
HNSCC enhanced α5β1 integrin expression endowing cells 
with an aggressive phenotype [10, 11]. It is obvious that 
beside FN, collagen also efficiently promotes evasion 
out of the tumor mass. However, in primary tumors of 
metastatic cases of oral squamous cell carcinoma (OSCC), 
the expression of various ECM molecules such as laminin 
or collagen is decreased, while the expression of FN is 
increased when compared with the non-metastatic cases 
[44]. Anti-α2 blocking antibodies were reported not to 
affect the invasion of OSCC cells in contrast to those 
targeting α5 [45]. Coupled to the fact that α5β1 integrin 
antagonist totally blocked migration, evasion and 
invasion, data suggest that collagen/α2β1 integrin are not 
crucial for HNSCC metastasis in contrast to fibronectin/
α5β1 integrin that seems to efficiently drive such process. 
However it remains true that if cells evolve in a collagen-
rich environment targeting α2β1 integrins seems an efficient 
anti-metastasis strategy as evasion of the tumor mass is 
totally abolished by anti-β1 antibodies as well as by the 
silencing of the α2 integrin subunit. In addition, α5β1 
integrin antagonist K34c significantly altered the viability 
of shRNAcav-1-cells and to a lesser extent of control cells 
that lead to a significant reduction of the clonogenic 
survival and therefore the self renewal capacity of SCC9 
cells. Silencing α2β1 integrin has no effect. α5β1 integrin 
antagonist were previously reported to significantly alter 
the proliferation of glioblastoma cell lines [43, 46]. Data 
suggest therefore that α5β1 integrin plays a crucial role in 
the viability of HNSCC cells. In addition, α5β1 integrin 
was recently described as a master regulator of anoïkis 
in hepatocellular cancer [47]. In accordance, preliminary 
study showed that cells expressing low levels of Cav1 
exerted strong resistance to anoïkis (not shown), a 
prerequisite for systemic circulation and secondary tumor 
formation in distant organs. Anti-α5β1 integrins therapy 
might therefore be a new therapeutic option for the “R1” 
subgroup of patient exerting low levels of Cav1 expression 
in order to prevent the development of metastasis but also 
the development of primary “R1” tumours.
In conclusion, our study showed for the first time 
that primary tumors from patients at high risk of distant 
metastasis express very low level of Cav1. It also clearly 
shows that low or no expression of Cav1 correlates with 
adverse prognosis. Disappearance of Cav1 enables cells to 
undergo EMT leading to increased motility, evasion and 
invasion capacities due to increased production of FN, an 
overexpression of its receptor α5β1 integrin and MMPs. 
Our study uncovered a new target that might open new 
therapeutic options for the clinical management of those 
patients. Targeting α5β1 integrins might not only prevent 
metastasis of HNSCC but also reduce the development 
of the primary tumor by reducing tumor cell viability. 
In conclusion, Cav1 detection might be taken into 
consideration in the future in the clinic not only to identify 
patients at high risk of metastasis but also to select patient 
who might benefit from an anti-integrin therapy.
MATERIALS AND METHODS
Cell lines, culture conditions
SCC9 cell lines were purchased from the ATCC and 
grown in DMEM-F12 (PAN Biotech) supplemented with 
2mmol/L L-glutamine, 0.4µg/mL hydrocortisone (Sigma) 
and 10% FBS (Gibco). Cell lines were authenticated as 
described in suppl. material and methods.
Human tissue samples
All tumor specimens (N = 68) were collected, stored 
and used with the patients’ informed consent. Patients 
from the North-East region of France underwent initial 
surgical resection of their localized HNSCC between 
1989 and 2002. Hematoxylin-eosin slides of paraffin-
embedded tumor (FFPE) specimens were examined by 
two pathologists. All of the tumors were squamous cell 
carcinomas. For detailed patients demographics, see 
Suppl. Table 1. Gene expression assays were performed 
on total RNA from frozen tumor tissues as described in 
[6] (see also Suppl. Material and Methods). The following 
genes were evaluated: Cav-1, E-Cadherin, Twist, Vimentin 
(see suppl. Table 2 for the sequence of specific primers). 
The expression of Cav1 and α5 integrin subunit was 
evaluated by immunohistochemical analysis (IHC) as 
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described in [48] (see also suppl. material and methods).
Short interfering RNA and plasmids
ShRNA (OpenBiosystems) were transfected at 4 
μg using 10µg/mL Arrest In™ and stable cell lines were 
selected with 1 µg/mL puromycine. SiRNA (Dharmacon) 
were transfected at 100 nmol/L using Lipofectamine™ 
2000 (Invitrogen). Efficiency of protein silencing was 
determined by western blotting and RT-qPCR. 
Chemicals
The compound 34c (2-(S)-2,6-dimethlybenzamido)-
3-[4-(3-pyridin-2-ylaminopro oxy)-phenyl] propionic 
acid) named K34c [12] was synthesized in our laboratory 
according the procedure described by Heckmann et al. 
[49]. Compound 1 [26] is one of the most selective non 
peptidic α5β1 integrin antagonist and was synthetized (as 
the compound 44) as described in Heckmann et al. [49]. 
OS2966, an anti-β1 integrin blocking antibody was kindly 
provided by OncoSynergy.
Real-time quantitative PCR
RNA was extracted as previously described [11]. 
mRNA expression was evaluated by relative quantitative 
RT-qPCR analysis using the StepOne Plus (Applied 
Biosystems) FastSYBRGreen PCR detector with primers 
(Invitrogen) described in suppl. Table 2. Target cDNA 
expression was quantified using the comparative ΔΔCt 
method with 18S rRNA as an internal control. 
Western blot
Cells were lysed (1% Triton-X100, NaF 100 
mmol/L, NaPPi 10 mmol/L, Na3VO4 1mmol/L in PBS, 
supplemented with Complete anti-protease cocktail; 
Roche) and 1-20 µg of protein was separated by SDS-
PAGE (BioRad) and transferred to PVDF membranes 
(Amersham). Blots were probed with various antibodies 
described in suppl. Table 3. Proteins were visualized 
with enhanced chemiluminescence using the LAS4000 
imager and densitometry analysis was performed using 
the ImageQuant Software (GE Healthcare).
Immunostaining of secreted fibronectin
Cells were plated at 2x105 cells per chamber in 
Lab-Tek II CC2 chamber slide (Nunc) for 24 hours. Cells 
were fixed 10 minutes at room temperature with 4% PFA, 
blocked 1 hour with 1% BSA and stained for extracellular 
secreted fibronectin (1:200) 1 hour at room temperature. 
After extensive wash, anti-Alexa546 was incubated 
an additional 1 hour at room temperature. Slides were 
mounted using Prolon Gold antifade reagent (Invitrogen) 
and observed using a fluorescent microscope (AXIO, 
Zeiss) with a 4X magnification.
Growth assay
shRNActrl and shRNAcav1-transfected SCC9 were 
counted at each passage after plating at similar density 
using the TC20 cell counter (BioRad). 
Clonogenic assay
Clonogenic assays were performed as previously 
described [50]. Data were expressed as surviving fraction 
as described by Cosset et al. [10]. Plating efficiency are 
0.23±0.02, and 0.17 ± 0.02 for shRNActrl and shRNAcav1-
transfected SCC9 respectively.
Single cell tracking
Cells were seeded at 500 cells/well with 1µg/
mL Hoechst3342 (Sigma) in µClear 96 well black plate 
(Dutscher) in L-15 medium (Sigma) supplemented with 
10%FBS. After 24 hours, medium was removed and fresh 
medium containing DMSO or 20 µmol/L compound 1 was 
added. Migration was followed by fluorescent microscopy 
(IN Cell Analyzer 1000, GE Healthcare) during 6 hours. 
Analyses were performed only on cells tracked during the 
entire assay. Speed and trajectories were computed with 
Excel software as previously reported [26].
Spheres evasion assay
Cells were seeded at 1x104 per 100µL of regular 
culture supplemented with 20% methylcellulose per 
well in 96 well plate with round bottom for 12 hours to 
allow spheroid formation. Spheroids were collected and 
seeded in plastic, fibronectin- or collagen-coated (10µg/
mL) 24 well plates (1 sphere/well) for additional 12 hours 
to allow evasion of cells from attached spheres. Pictures 
were taken using the Evos Core microscope (AMG) with 
a 10X magnification. Results were expressed as the area of 
evasion of cells from the area of the attached sphere (total 
area - sphere area) determined using the ImageJ software 
and results are expressed in pixels. 
Invasion assay
Lower chambers of BD BioCoat Matrigel invasion 
chamber (24 well, 8 µm pores, BD Biosciences) were 
filled with 750µl of 10% FCS culture medium. 2.5x104 
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cells were seeded in the upper compartment in 0% FCS 
culture medium containing DMSO or 20 µM K34c for 22 
hours according to manufacturer’s instructions. Cells that 
had transmigrated and adhered to the lower surface were 
fixed in glutaraldehyde for 15 minutes, stained with 0.1% 
crystal violet for 30 minutes and counted. No cells were 
detected in the lower chamber. 
Statistical analysis
Data are represented as mean ± SEM. In all cases, 
n refers to the number of independent experiments. 
Statistical analyses were done with the Student’s t-test or 
ANOVA where p < 0.05 was considered significant.
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